RecruitingPhase 2NCT07062588
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
Studying Osteogenesis imperfecta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Angitia Incorporated Limited
- Principal Investigator
- Ann Zovein, MD, MDAngitia Incorporated Limited
- Intervention
- AGA2115(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2029
Study locations (26)
- Phoenix Children's, Phoenix, Arizona, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
- Indiana University School of Medicine, Department of Medicine and Pediatrics Division of Endocrinology, Indianapolis, Indiana, United States
- Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
- University of Nebraska Medical Center (UNMC) - Diabetes and Endocrinology Center, Omaha, Nebraska, United States
- New Mexico Clinical Research & Osteoporosis Center, Inc. (NMCROC), Albuquerque, New Mexico, United States
- The Ohio State University Wexner Medical Center (OSUWMC), Columbus, Ohio, United States
- Oregon Health & Science University (OHSU) - The Harold Schnitzer Diabetes Health Center (HSDHC) - Endocrinology Clinic, Portland, Oregon, United States
- Vanderbilt University Medical Center (VUMC) - Eskind Diabetes Clinic, Nashville, Tennessee, United States
- Instituto de Investigaciones Metabolicas Dr. Zanchetta - Sede Centro, Buenos Aires, Argentina
- Monash University-Monash Medical Centre (MMC), Melbourne, Australia
- Royal Melbourne Hospital, Parkville, Australia
- Royal North Shore Hospital (RNSH), Saint Leonards, Australia
- Adults Westmead Hospital, Westmead, Australia
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07062588 on ClinicalTrials.govOther trials for Osteogenesis imperfecta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07366086Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaAmgen
- RECRUITINGNANCT07412782REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)Meyer Children's Hospital IRCCS
- RECRUITINGNANCT07478224An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type IUniversity Hospital, Ghent
- RECRUITINGNCT07287241Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis ImperfectaIstituto Ortopedico Rizzoli
- ACTIVE NOT RECRUITINGPHASE3NCT06636071Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc
- RECRUITINGPHASE3NCT05972551Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaAmgen
- RECRUITINGNANCT05927389Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis ImperfectaUniversity Hospital, Toulouse
- ACTIVE NOT RECRUITINGPHASE3NCT05768854Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc